Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Diabetic Medicine

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-5491.2005.01567.xPMID 16026367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin Prevents Weight Gain by Reducing Dietary Intake During Insulin Therapy in Patients with Type 2 Diabetes Mellitus

  2012cited by this paper
• One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

  2004cited by this paper
• Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

  2004cited by this paper
• No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes

  2003cited by this paper
• The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

  2003cited by this paper
• NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.

  2002cited by this paper
• Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.

  2002cited by this paper
• Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.

  2002cited by this paper
• Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1

  2002cited by this paper
• Presence of glutamine:fructose-6-phosphate amidotransferase for glucosamine-6-phosphate synthesis in endothelial cells: effects of hyperglycaemia and glutamine

  2001cited by this paper
• Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

  2001cited by this paper
• Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

  2000cited by this paper
• Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

  2000cited by this paper
• Measurement of visceral adipose tissue by DXA combined with anthropometry in obese humans

  2000cited by this paper
• Glucagon-like peptide-1: a potent regulator of food intake in humans

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

  1998cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1

  1998cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1998cited by this paper
• Distal Small Bowel Hormones (Correlation with Fasting Antroduodenal Motility and Gastric Emptying)

  1998cited by this paper
• Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

  1998cited by this paper
• Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

  1997cited by this paper
• Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.

  1997cited by this paper
• Attenuated GLP-1 secretion in obesity: cause or consequence?

  1996cited by this paper
• A role for glucagon-like peptide-1 in the central regulation of feeding

  1996cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

  1993cited by this paper
• Glucagon-like peptide-1, a new hormone of the entero-insular axis

  1992cited by this paper
• Glucagon-like peptide-1, a new hormone of the entero-insular axis.

  1992cited by this paper

• GLP-1 receptor agonists in the context of cancer: the road ahead

  2025cites this paper
• Chronic metabolic effects of novel gut-oriented small-molecule GPR119 agonists in diet-induced obese mice.

  2024cites this paper
• Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity

  2024cites this paper
• The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy

  2024cites this paper
• Pharmacological Advances in Incretin-based Polyagonism - What we know and what we don'tt.

  2024cites this paper
• First-Time Prescribing of GLP-1 Receptor Agonists from 2018-2023: A Descriptive Analysis

  2023cites this paper
• Incretin hormones and type 2 diabetes

  2023cites this paper
• The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months

  2023cites this paper
• Effects of liraglutide on weight reduction and metabolic parameters in obese patients with and without type 2 diabetes mellitus

  2022cites this paper
• The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

  2020cites this paper
• Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial

  2020cites this paper
• Efficacy and safety of polyethylene glycol loxenatide as add‐on to metformin in patients with type 2 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3b trial

  2020cites this paper
• The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease

  2020cites this paper
• Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure.

  2019cites this paper
• Sustained release of exendin‐4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes

  2019cites this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonist equal in the treatment of type 2 diabetes?

  2019cites this paper
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

  2016cites this paper
• Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.

  2016cites this paper
• Povezanost inkretinske terapije i nealkoholne steatoze jetre u bolesnika sa šećernom bolesti tipa 2

  2016cites this paper
• Treatment Strategies for Type 2 Diabetes Based on Incretin Action

  2016cites this paper
• Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice

  2015cites this paper
• Drug Information Rounds

  2015cites this paper
• Effects of E 2 HSA , a Long-Acting Glucagon Like Peptide-1 Receptor Agonist , on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db / db Mice

  2015cites this paper
• Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown

  2015cites this paper
• Exendin-4 modified by Evans blue or derivatives of Evans blue and preparation method and application of Exendin-4

  2015cites this paper
• Importancia del control glucémico posprandial en el paciente con diabetes mellitus tipo 2

  2015cites this paper
• Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.

  2014cites this paper
• Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients

  2014cites this paper
• GLP-1 improves neuropathology after murine cold lesion brain trauma

  2014cites this paper
• Influence of Liraglutide Alone and in Combination With Glimepiride on Body Weight in Obese-Diabetic Rabbits

  2013cites this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013cites this paper
• Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

  2013cites this paper
• Recomendaciones para el empleo de antidiabéticos orales en la diabetes tipo 2

  2012cites this paper
• Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity

  2012cites this paper
• [Liraglutide: new results in the treatment of type 2 diabetes mellitus].

  2012cites this paper
• Current challenges in type 2 diabetes

  2012cites this paper
• GLP-1 receptor agonists: A clinical perspective on cardiovascular effects

  2012cites this paper
• Manejo terapéutico de la hiperglucemia en la diabetes tipo 2. Antidiabéticos orales

  2012cites this paper
• New Drugs for Type 2 Diabetes Mellitus

  2012cites this paper
• Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models

  2012cites this paper
• Review of the therapeutic uses of liraglutide.

  2011cites this paper
• [Cell therapy for diabetes mellitus: beyond stem cells].

  2011cites this paper
• Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial

  2011cites this paper
• Is Liraglutide Safe and Effective as a Monotherapy for the Treatment of Obesity in Type 2 Diabetics and Healthy Individuals

  2011cites this paper
• New Therapeutics for Diabetes Using Incretin Hormone

  2011cites this paper
• TERAPIA CELULAR PARA EL TRATAMIENTO DE LA DIABETES: MAS ALLA DE LAS CELULAS MADRE

  2011cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

  2011cites this paper
• Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.

  2011cites this paper
• SAFETY OF THE LIRAGLUTIDE TREATMENT

  2011cites this paper
• Liraglutide: once‐daily GLP‐1 agonist for the treatment of type 2 diabetes

  2011cites this paper
• Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials

  2011cites this paper
• Liraglutide: Clinical Pharmacology and Considerations for Therapy

  2011cites this paper
• GLP‐1 playing the role of a gut regulatory compound

  2011cites this paper
• Glucagon-like peptide analogues for type 2 diabetes mellitus.

  2011cites this paper
• Liraglutide

  2011cites this paper
• Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility.

  2010cites this paper
• Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide

  2010cites this paper
• Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials

  2010cites this paper
• Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

  2010cites this paper
• Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

  2010cites this paper
• Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

  2010cites this paper
• Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use

  2010cites this paper
• Metformin - more than 'gold standard' in the treatment of type 2 diabetes mellitus.

  2010cites this paper
• Original Article: Treatment Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

  2010cites this paper
• Evidence review : liraglutide for the treatment of type 2 diabetes

  2010cites this paper
• Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

  2010cites this paper
• Early clinical studies with liraglutide

  2010cites this paper
• The Role of Incretins in Insulin Secretion

  2010cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2010cites this paper
• Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

  2010cites this paper
• Emerging role of GLP-1 receptor agonists in the treatment of obesity

  2010cites this paper
• Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes

  2010cites this paper
• Glycaemic control in type 2 diabetes: targets and new therapies.

  2010cites this paper
• Contemporary management of patients with Type 2 diabetes

  2010cites this paper
• Diabesity: therapeutic options

  2010cites this paper
• Clinical Studies of Liraglutide, a Novel, Once‐Daily Human Glucagon‐Like Peptide‐1 Analog for Improved Management of Type 2 Diabetes Mellitus

  2009cites this paper
• [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].

  2009cites this paper
• Liraglutide: a new treatment for type 2 diabetes.

  2009cites this paper
• Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long‐Acting, Potent Glucagon‐Like Peptide‐1 Analog

  2009cites this paper
• Exenatide once weekly for the treatment of type 2 diabetes.

  2009cites this paper
• Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

  2009cites this paper
• Stoffwechsel-Kontrolle bei intensivpflichtigen Patienten mit Typ 2 Diabetes durch Gabe von Glucagon-like Peptide 1

  2009cites this paper
• Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2009cites this paper
• Potential of liraglutide in the treatment of patients with type 2 diabetes

  2009influential citation
• Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

  2009cites this paper
• Liraglutide Effect and Action in Diabetes (LEAD™) trial

  2009cites this paper
• Exenatide once weekly for the treatment of type 2 diabetes

  2009cites this paper
• Liraglutide

  2009cites this paper
• Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

  2008cites this paper
• Metformin therapy and clinical uses

  2008cites this paper
• More Choces Than Ever Before

  2008cites this paper
• Metformin: a review.

  2008cites this paper
• Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

  2008cites this paper
• The role of insulin analogs in type 2 diabetes in the rural community.

  2008cites this paper
• New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly

  2008cites this paper
• Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

  2008cites this paper
• Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.

  2008cites this paper
• Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

  2008cites this paper
• Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents

  2008cites this paper
• The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.

  2008cites this paper